Audentes Therapeutics Inc

Audentes Therapeutics — Investor Presentation (September 2016)

34 slides from Audentes Therapeutics's investor presentation, Sep 28, 2016

  1. Slide 1: Audentes Corporate Overview

    September 2016 Audentes Corporate Overview NASDAQ: BOLD Exhibit 99.1

  2. Slide 2: Safe Harbor

    Safe Harbor Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company’s current views about future events and are subject to risks, uncertainties, assumptions and changes in circumstances that may cause event

  3. Slide 3: Audentes Therapeutics

    Audentes Therapeutics Developing gene therapy products to transform the lives of rare disease patients with limited or no treatment options Rare disease and AAV gene therapy strategic focus Internal manufacturing provides core strategic advantage Focused selection criteria for current and future pro

  4. Slide 4: Leadership Team with Outstanding Experience

    Matthew Patterson President and Chief Executive Officer Natalie Holles Senior VP and Chief Operating Officer Thomas Soloway Senior VP and Chief Financial Officer Suyash Prasad, M.D. Senior VP and Chief Medical Officer John Gray, Ph.D. Senior VP, Research and Development Mary Newman Senior VP, Regula

  5. Slide 5: Multiple 2016 Sector Catalysts

    Multiple 2016 Sector Catalysts Hemophilia A&B - Spinal Muscular Atrophy Choroideremia - X-linked Retinoschisis Parkinson’s - Sanfilippo B AAV9-SMN for SMA Type 1 A devastating rare disease affecting infants Compelling proof-of-concept for treating neuromuscular disease with systemic AAV gene therapy

  6. Slide 6: Focused Approach to Product Candidate Selection

    Focused Approach to Product Candidate Selection Value Drivers Audentes Approach High-value targets Serious life-threatening rare diseases with limited or no treatment options Monogenic diseases with well-understood biology High potential for meaningful clinical benefits Leading AAV science Well-char

  7. Slide 7: Robust Pipeline

    [Enter Text Here]---[Enter Text Here] Robust Pipeline Product Candidate(Indication)Stage of DevelopmentPlanned IND/CTA SubmissionPreliminary Data ExpectedCommercial RightsDiscoveryLead OptimizationIND- EnablingPhase 1/2AT132(XLMTM)Q1 2017Q4 2017AT342(Crigler-Najjar Syndrome)Q4 2016Q4 2017AT982(Pompe

  8. Slide 8: Internal cGMP manufacturing capability

    Internal manufacturing capability is a significant advantage in AAV field Superior control over timelines, costs, and intellectual property Opportunity for rapid addition of new programs Audentes facility established and on-line 38,000 square foot cGMP manufacturing facility in South San Francisco 2

  9. Slide 9: Audentes Manufacturing Positioned for Leadership in AAV Production

    Audentes Manufacturing Positioned for Leadership in AAV Production Mammalian cell-based production Natural host for AAV Significant regulatory history with HEK293 Robust, industrial scale suspension culture system Proprietary downstream purification optimizes product quality and purity Initial capac

  10. Slide 10: AT132 X-linked myotubular myopathy

    AT132 X-linked myotubular myopathy

  11. Slide 11: XLMTM: A Fatal Disease with No Treatment Options

    Serious, life-threatening rare disease Significant impairment of respiratory and neuromuscular function Estimated 50% mortality by 18 months Incidence: 1 in 50K newborn males Monogenic, well-understood biology MTM1 gene encodes myotubularin, enzyme required for normal development and function of ske

  12. Slide 12: AT132 Improves Survival in XLMTM Mouse and Dog Models

    A single treatment with AT132 Results In Dramatic Improvement & Survival in XLMTM Mouse and Dog Models M. K. Childers et al., Sci Transl Med, 2014; Buj-Bello, et al. Human Molecular Genetics, 2008; Note: vector dosing numbers have been adjusted from publication as a result of improvements in titrati

  13. Slide 13: AT132 Improves Survival in XLMTM Dogs

    Treatment with AT132 Results in Dramatic Improvement and Survival in XLMTM Dogs *Dogs 3, 4 and 5, the three dogs treated in the proof-of-concept canine study, achieved a statistically significant improvement in survival.

  14. Slide 14: AT132 Dose Dependent Improvement in XLMTM Dogs

    AT132 Improves Survival, Neuromuscular and Respiratory Outcomes in a Dose Dependent Manner in XLMTM Dogs Systemic Delivery Dose-Escalation Study in XLMTM Canine Model Mack, D., et. al. ASGCT, 2015 n=19 Infusion of AT132 in week 10 AT132 treated dogs assessed over 45 weeks Arm n Normal 6 XLMTM + Plac

  15. Slide 15: AT132 Clinical Development

    AT132 Clinical Development Planned Path to Phase 1/2 Data RECENSUS Retrospective Chart Review (n=120) XLMTM natural history Historical control for ASPIRO INCEPTUS Clinical Assessment and Phase 1/2 Run-in Study (n=12 to 15) Ongoing, prospective evaluation of disease presentation Longitudinal baseline

  16. Slide 16: AT132 for XLMTM Opportunity Summary

    AT132 for XLMTM Opportunity Summary Robust Preclinical POC Path to Approval Compelling Market Potential Consistent significant impact on muscle function and survival across two models of disease Clear dose-dependent efficacy Strong safety profile IND/CTA planned Q1:17 Preliminary clinical data expec

  17. Slide 17: AT342 Crigler-Najjar syndrome

    AT342 Crigler-Najjar syndrome

  18. Slide 18: Crigler-Najjar Syndrome

    Crigler-Najjar Syndrome A Rare Disease that Leads to Neurological Damage and Death Serious, life-threatening rare disease Significant bilirubin accumulation that can lead to irreversible neurological damage and death Current treatments: > 12 hours/day of phototherapy, liver transplant Estimated inci

  19. Slide 19: AAV8-UGT1A1 Reduces Bilirubin Levels in Mouse Model

    AAV8-UGT1A1 Reduces Bilirubin Levels in a Crigler-Najjar Mouse Model Single intraperitoneal injection of AAV8-UGT1A1 (3.2 x 1011 vg/mouse) in 4 day old affected mice Bilirubin levels remained below the level at which neurological damage is observed for the 17-month study duration Results suggest tha

  20. Slide 20: AT342 Development Plan

    AT342 Development Plan Planned Path to Phase 1/2 Data Clinical Assessment and Phase 1/2 Run-in Study (n=12 to 15) Prospective evaluation of disease presentation Longitudinal baseline and within-patient control for Phase 1/2 Clinical Study Facilitate enrollment and other operational aspects of Phase

  21. Slide 21: AT342 for Crigler-Najjar Opportunity Summary

    AT342 for Crigler-Najjar Opportunity Summary Robust Preclinical POC Path to Approval Compelling Market Potential Rapid, significant, and durable reductions in bilirubin and need for phototherapy in mouse model Established safety track record for liver-directed AAV8 therapies IND/CTA planned Q4:16 Pr

  22. Slide 22: AT982 Pompe Disease

    AUDENTES 2» AT982 POMPE DISEASE

  23. Slide 23: Pompe Disease

    Pompe Disease A Rare, Severe, Progressive Neuromuscular Disease Lipinksi, Shawn. Molecular Genetics and Metabolism, 2012; Lacana, et al., Amer. J. Medical Genetics, 2012; International Pompe Association, Pompe Community and United Pompe Foundation Serious, life-threatening rare disease Severe muscle

  24. Slide 24: AT982 Significant Improvement in Pompe KO Mice

    P ≤ 0.0001 P ≤ 0.05 P ≤ 0.001 P ≤ 0.01 P ≤ 0.05 P ≤ 0.001 P ≤ 0.001 P ≤ 0.001 P ≤ 0.001 P ≤ 0.01 P ≤ 0.01 Treatment with AT982 Results In Significant Improvement in Pompe KO Mice Falk et al, Molecular Therapy–Methods & Clinical Development,2015 GAA Activity Total Respiratory Cycle Time Improved (3 m

  25. Slide 25: AT982 Development Plan

    AT982 Development Plan Phase 1/2 proof-of-concept (POC) IND planned Q4:16 Phase 1/2 POC study (n=~8 Pompe adults on ERT) Randomized, blinded, within patient control Intramuscular injection to tibialis anterior (TA) Objectives: Safety and GAA expression after single AT982 injection Exploring potentia

  26. Slide 26: AT982 for Pompe Opportunity Summary

    AT982 for Pompe Opportunity Summary Robust Preclinical POC Path to Approval Compelling Market Potential Significant, durable reductions in GAA, improvements in cardiac, respiratory function Clear improvements over ERT in Pompe mouse model Regulatory guidance obtained, IND planned Q4 2016 Preliminary

  27. Slide 27: AT307 CPVT

    AT307 Catecholaminergic polymorphic ventricular tachycardia (CPVT)

  28. Slide 28: CASQ2-CPVT: A Life-Threatening Inherited Arrhythmia

    Serious, life-threatening rare disease Ventricular arrhythmias and sudden death in response to stress and/or exercise Prevalence estimated at > 6,000 in addressable markets with mortality of 30-50% by age 30 Monogenic , well-understood biology Autosomal recessive form (CASQ2) : gene encodes calseque

  29. Slide 29: AT307 Prototype Prevents VT in Newborn and Adult Mice

    AT307 Prototype Prevents VT in Newborn Mice and Reverses VT in Adult Mice A single administration of an AT307 prototype achieved: Near normal levels of CASQ2 protein expression Reduction in pre-arrhythmic events and ventricular tachycardia to normal levels in both newborn and adult mice Denegri et a

  30. Slide 30: AT307 for CASQ2-CPVT Opportunity Summary

    AT307 for CASQ2-CPVT Opportunity Summary Robust Proof-of-Concept Path to Approval Compelling Market Potential Significant, durable CASQ2 expression; reduction in ventricular tachycardia in newborn and adult disease model mice IND/CTA planned in 2017 Clear efficacy measures for Phase 1/2 study Orphan

  31. Slide 31: Financial Overview

    AUDENTES 2» FINANCIAL OVERVIEW

  32. Slide 32: Financial Summary

    Financial Summary $85M IPO in July 2016 with leading life sciences investors (NASDAQ: BOLD) June 30, 2016 cash balance $60.7M of cash and equivalents, short-term investments and short-term restricted cash at June 30 $75.5M IPO proceeds net of underwriting discounts, commissions and offering costs $1

  33. Slide 33: Audentes Highlights

    Audentes Highlights Focus Expertise Leadership Manufacturing Catalysts Industry-leading AAV gene therapy company Compelling pipeline of rare disease product candidates Internal cGMP manufacturing expected Q4:16 Future capacity expansion to support full commercial production Proven management team wi

  34. Slide 34: September 2016 Corporate Overview

    September 2016 Corporate Overview NASDAQ: BOLD

Audentes Therapeutics — Investor Presentation (September 2016) on 6ix